Pub. Date : 2019 Sep-Oct
PMID : 31786845
5 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Effect of PD98059 on chemotherapy in patients with colorectal cancer through ERK1/2 pathway. | 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one | mitogen-activated protein kinase 3 | Homo sapiens |
| 2 | PURPOSE: To investigate the effects of MAPK/ERK signaling transduction pathway inhibitor PD98059 combined with paclitaxel on the proliferative, invasive and apoptotic abilities of colorectal cancer cells. | 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one | mitogen-activated protein kinase 3 | Homo sapiens |
| 3 | PURPOSE: To investigate the effects of MAPK/ERK signaling transduction pathway inhibitor PD98059 combined with paclitaxel on the proliferative, invasive and apoptotic abilities of colorectal cancer cells. | 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one | mitogen-activated protein kinase 3 | Homo sapiens |
| 4 | CONCLUSIONS: Inhibitor PD98059 combined with paclitaxel can affect the expression of ERK1/2 in ERK1/2 signaling pathway, effectively inhibit the proliferation and invasive abilities of CRC cells, increase the apoptotic ability of CRC cells, and is expected to become a potential drug for clinical treatment of CRC. | 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one | mitogen-activated protein kinase 3 | Homo sapiens |
| 5 | CONCLUSIONS: Inhibitor PD98059 combined with paclitaxel can affect the expression of ERK1/2 in ERK1/2 signaling pathway, effectively inhibit the proliferation and invasive abilities of CRC cells, increase the apoptotic ability of CRC cells, and is expected to become a potential drug for clinical treatment of CRC. | 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one | mitogen-activated protein kinase 3 | Homo sapiens |